Renal cancer accounts for more than 64 000 new cases per year in the Unites States, and causes approximately 13 500 deaths yearly ([@bib24]). Worldwide incidence and mortality rates are rising at approximately 2--3% per decade ([@bib11]). Sunitinib (Sutent; Pfizer, New York, NY, USA) is an orally active, multi-targeted inhibitor of VEGFR1-3, PDGFR, KIT, FLT3, CSF-1 and RET ([@bib4]), approved for the treatment of metastatic renal cell cancer (mRCC; [@bib17]). Importantly, sunitinib-induced toxicities (mainly diarrhoea, hand-foot syndrome, fatigue and hypertension) may limit the patient\'s ability to receive full-dose treatment. In the sunitinib arm of the pivotal phase III trial, these toxicities resulted in dose reductions in 50% and treatment termination in 19% of the patients ([@bib16]).

Little is known on factors predicting sunitinib toxicity. Polymorphisms in *CYP3A5* (rs776746) might identify a subset of patients prone to toxicity-related dose reductions ([@bib10]). However, these polymorphisms are not routinely assessed in daily practice.

Recently, the condition of low muscle mass, named sarcopenia ([@bib6]; [@bib9]), has been studied in cancer patients, in whom sex-specific cut-off values based on mortality risks have been determined ([@bib21]). Sarcopenia is a significant predictor of toxicity in mRCC patients treated with sorafenib (an orally active multi-kinase inhibitor that targets BRAF, RET, PDGFR-b, VEGFR-1 and VEGFR-2 ([@bib28])), in particular those with a body mass index (BMI)\<25 kg m^−2^ ([@bib1]). As well, sarcopenia predicts treatment-induced toxicity in hepatocellular carcinoma patients treated with sorafenib ([@bib14]).

The purpose of the present analysis was to investigate whether sarcopenia could predict the occurrence of early dose-limiting toxicities (DLTs) in mRCC patients treated with sunitinib. We hypothesised that an increased toxicity would be observed in sarcopenic patients.

Materials and methods
=====================

Participants
------------

We performed a retrospective, electronical, medical record review of all consecutive mRCC patients treated with sunitinib in our institution from June 2006 to March 2012.

Ethics
------

The study was approved by the local ethics board according to good clinical practice and applicable laws, and the declaration of Helsinki.

Treatment, toxicity and activity assessment
-------------------------------------------

Adult mRCC outpatients received sunitinib at a starting dose of 50 mg per day, 4 weeks/6, 37.5 mg continuous daily dosing (CDD) or 25 mg CDD according to their Eastern Cooperative Oncology Group performance status (ECOG PS) and co-morbidities, at the discretion of the treating physician, as described by other authors ([@bib7]; [@bib3]). Toxicity was assessed at each visit, every 2 weeks (or before if clinically indicated) during the first cycle, then monthly.

In the case of grade 3 or 4 toxicity according to the National Cancer Institute Common Terminology Criteria v3.0, sunitinib was discontinued, except for patients with grade 3 hypertension in whom antihypertensive drugs were introduced according to current guidelines ([@bib13]). Depending on toxicity resolution, sunitinib was resumed at full dose or at decreased doses, or permanently discontinued, at the discretion of the treating physician.

A DLT was defined as any toxicity leading to a dose reduction, temporary or permanent discontinuation of treatment. Following the design of a previous study ([@bib20]), only DLTs occurring during the first cycle of treatment were examined for the present analysis. A cycle of treatment was determined as a period of 6 weeks.

Treatment activity was assessed every two cycles by CT scan, or before if clinically indicated, according to RECIST v1.0 ([@bib26]).

Anthropometric measurements
---------------------------

Weight was measured with a medical balance beam scale, and height was measured with a stadiometer. The BMI was calculated (weight (kg)/height^2^ (m^2^)) and the World Health Organization categories were used: underweight, BMI\<18.5; normal, 18.5⩽BMI⩽24.9; overweight, 25⩽BMI⩽29.9; obesity, BMI⩾30. Body surface area (BSA) was calculated using the Mosteller formula: BSA (m^2^)=((height (cm) × weight (kg))/3600)^1/2^.

Image analysis
--------------

Body composition was evaluated by assessing muscle tissue areas on CT-scan images, as previously described ([@bib12]; [@bib15]). CT scans had been performed for diagnostic or follow-up purposes within no more than 30 days before initiation of sunitinib. Images were analysed using ImageJ software v1.42q (National Institutes of Health, <http://rsb.info.nih.gov/ij>). The third lumbar vertebra (L3) was chosen as a standard landmark, as previously described ([@bib1]). Muscles were identified based on their anatomic features, and the structure of those specific muscles was quantified based on pre-established thresholds of skeletal muscle tissue (−29 to +150 Hounsfield units; [@bib15]). Cross-sectional areas (cm^2^) of the sum of all of these muscles were computed and the mean value for two consecutive images was computed for each patient. These values were normalised for stature ([@bib18]; [@bib21]) and expressed in units of cm^2^ m^−2^. The sex-specific cutoff values for sarcopenia (55.4 cm^2^ m^−2^ for males and 38.9  cm^2^ m^−2^ for females) determined in cancer patients were used as done by others in mRCC patients ([@bib1]). The total lumbar--skeletal muscle cross-sectional area is linearly related to the whole-body muscle ([@bib23]; [@bib18]) and the total lean body mass (LBM) was estimated from muscle cross-sectional areas as described by [@bib18]: LBM (kg)=(0.30 × (skeletal muscle area at L3 using CT (cm^2^))+6.06). As the body composition analysis was done *a posteriori*, treating physicians were blinded to patients\' body composition status (sarcopenic or not).

Statistical analysis
--------------------

Prevalence of toxicity was compared using Fisher\'s exact test, and Mann--Whitney\'s test was used for the comparison of continuous variables. All *P*-values were two-sided, and the level of significance was *P*\<0.05. Multivariate analysis of factors predicting early DLTs was conducted using logistic regression with 3000 bootstrap iterations, including only factors predicting the occurrence of DLTs with a *P*-value\<0.05 by univariate analysis. Progression-free survival (PFS) and overall survival (OS) were measured from the date of first treatment administration to the date of disease progression or death for the former, and the date of death for the latter. Kaplan--Meier estimates of the distribution of times from baseline to outcome were computed, and the groups were compared using the log-rank test. Calculations were performed with NCSS 2007 software (NCSS, Kaysville, UT, USA).

Results
=======

Patients\' characteristics
--------------------------

From June 2006 to March 2012, 84 mRCC patients received sunitinib, among which 61 (73%) met all criteria for study analysis ([Figure 1](#fig1){ref-type="fig"}).

Baseline characteristics of patients treated with sunitinib are presented in [Table 1](#tbl1){ref-type="table"}. Briefly, 32 patients (52.5%) were sarcopenic and 20 (32.8%) were sarcopenic, and had a BMI \<25 kg m^−2^. The variables needed to assign a Memorial Sloan Kettering Cancer Center (MSKCC) risk score were missing for 11 patients, and those needed to assign a Heng score were missing for 15 patients. Some patients could be correctly assigned even with some missing data; for the others the most likely values were derived.

Sunitinib toxicity
------------------

Eighteen patients (29.5%) experienced a DLT during the first cycle of treatment ([Table 2](#tbl2){ref-type="table"}). In all cases but two, patients had multiple toxic effects of grade 2 and/or 3. Sunitinib was discontinued and resumed either at the same dose in three cases (16.5%) or at a lower dose in eight cases (44.5%). For the seven remaining patients (39%), sunitinib was permanently discontinued. [Table 2](#tbl2){ref-type="table"} shows therapy adjustments and the duration of subsequent sunitinib treatment after the occurrence of a DLT (median for the whole cohort: 31 weeks, range 6--150). Sunitinib was resumed in 40% of patients with sarcopenia and low BMI (for a median duration of 33 weeks, range 16--85), and in 75% of patients in the remaining patients (median duration: 31 weeks, range 6--150), *P*=0.06.

The comparison of anthropometric parameters between patients with or without early DLT is summarised in [Table 3](#tbl3){ref-type="table"}. Significant differences were observed regarding age (*P*=0.006), weight (*P*=0.007), BSA (*P*=0.004), LBM (*P*=0.006) and skeletal muscle L3 index (*P*=0.02). No difference was found regarding BMI or sarcopenia. The prevalence of DLT did not significantly differ in patients receiving 50 mg, 4 weeks/6, or CDD \<50 mgper day (*P*=0.31).

The comparison between patients with both sarcopenia and BMI \<25 kg m^−2^ with the remaining patients is summarised in [Table 4](#tbl4){ref-type="table"}. No difference was found regarding the starting dose, ECOG PS at beginning of treatment or classification according to the MSKCC risk group. [Figures 2A and B](#fig2){ref-type="fig"} illustrate the distribution of BMI, muscle index and early DLT for men and women, respectively. Overall, sarcopenic patients with BMI \<25 kg m^−2^ experienced significantly more DLTs (*P*=0.01; odds ratio=4.1; 95% CI: (1.3--13.3)), more cumulative grade 2 or 3 toxicities (*P*=0.008) and more grade 3 toxicities (*P*=0.04) during the first cycle. Permanent termination of sunitinib during the first cycle occurred in 30% of these patients compared with 2.4% of the remaining patients (*P*=0.01). Of note, acute vascular toxicities (microangiopathic haemolytic anaemia, thrombotic microangiopathy or reversible posterior leukoencephalopathy syndrome) were more frequent during the first cycle of treatment in this subset of patients (*P*=0.009). By multivariate analysis, the combination of sarcopenia and BMI\<25 kg m^−2^ was the only independent predictor of early DLTs (*P*=0.04).

Survival analysis
-----------------

The median PFS and OS for the study population (*n*=61) were 9.0 (95% CI: 6.4--11.8) and 22.1 months (95% CI: 14.0--26.0), respectively. No significant differences were observed between patients with sarcopenia and BMI\<25 kg m^−2^, and the remaining patients regarding median PFS (7.5 (95% CI: 3.9--10.1) *vs* 9.4 months (95% CI: 6.3--16.2), respectively; *P*=0.11; [Figure 3A](#fig3){ref-type="fig"}) and median OS (19.3 (95% CI: 14--20) *vs* 23.5 months (95% CI: 12.5--40.7), respectively; *P*=0.21; [Figure 3B](#fig3){ref-type="fig"}). When considering sarcopenic and non-sarcopenic patients, no significant differences were observed regarding PFS (*P*=0.71) or OS (*P*=0.75).

Discussion
==========

This retrospective analysis is the first evaluating the relationship between sarcopenia and early toxicity in patients treated with sunitinib for mRCC. We found that patients with sarcopenia and a BMI\<25 kg m^−2^ experienced significantly more DLTs, more cumulative grade 2 or 3 toxicities and more grade 3 toxicities during the first cycle.

Baseline characteristics of patients included in this analysis were similar to those observed in previous studies in mRCC patients ([@bib1], [@bib2]). Indeed, sarcopenic patients and sarcopenic patients with low BMI represented 52.5% and 32.8%, respectively, of all patients in the present cohort. A high proportion of patients experienced early DLTs, probably reflecting the toxicity profile of sunitinib in less-selected patients than those included in clinical trials. We found that low skeletal muscle area (and, therefore, low LBM) was significantly associated with the occurrence of early DLTs (*P*=0.006), but sarcopenia *per se* was not predictive for early DLTs (*P*=0.17).

[@bib1] observed that BMI\<25 kg m^−2^ associated with sarcopenia was a significant predictor of toxicity in mRCC patients treated with sorafenib. Hence, further analyses combining sarcopenia with low BMI were pre-planned. This subset of patients was found to be at particular risk of DLT during the first cycle, with 50% of patients experiencing a DLT, compared with 19.5% among other patients (*P*=0.01). This difference was related to the occurrence of more cumulative grade 2 or 3 toxicities, more cumulative grade 3 toxicities and more acute vascular toxicities. The sum of several toxicities, which were not individually dose limiting, lead to permanent termination of sunitinib in six patients (30%) with sarcopenia and BMI \<25 kg m^−2^, compared with only one patient (2.4%) in the remaining group (*P*=0.003).

Remarkably, the excessive toxicity observed in patients with sarcopenia and BMI \<25 kg m^−2^ did not translate into a significantly poorer PFS or poorer OS. The first explanation could lie in the fact that, following the occurrence of a DLT sunitinib was resumed in up to 40% of patients with sarcopenia and low BMI, for a median time of 33 weeks (range 16--85).

The second potential explanation is that efficient second-line treatment was given to five of the seven patients in whom sunitinib had been permanently withdrawn.

The excessive toxicity in patients with both sarcopenia and low BMI observed in this series is in line with previous findings, indicating that both conditions underlie a particular vulnerability to various anti-cancer agents.

An association between low BMI and increased toxicity has been reported in a population of 45 patients (85% with mRCC) treated with sunitinib ([@bib25]). In this population, grade 3 or 4 cardiotoxicity was associated with low BMI (mean 23.9 kg m^−2^ *vs* 27.1 kg m^−2^; *P*=0.03).

Sunitinib toxicity has also been associated with low BSA (a variable conditioned to height and weight, similar to BMI) in 82 advanced RCC patients treated with sunitinib ([@bib27]). In this population, DLTs occurred in 37 patients and were significantly related to low BSA (*P*=0.005). Interestingly, low BSA was also significantly associated with early DLT (*P*=0.002) in the present series.

Sarcopenia is associated with an increased toxicity of 5-fluorouracil ([@bib19]), capecitabine ([@bib20]), epiribucin ([@bib22]) and sorafenib ([@bib14]). Sarcopenia is also associated with poorer survival for obese patients with solid tumours of the lung or gastro-intestinal tract ([@bib21]), and with increased propensity for nosocomial infection and other complications ([@bib5]).

Finally, an increased toxicity could also be linked to higher drug exposure, in the same way it has been suggested for hepatocellular carcinoma sarcopenic patients treated with sorafenib ([@bib14]). Indeed, in the phase I trial of sunitinib ([@bib8]) most patients with DLT had combined sunitinib and SU012662 (sunitinib major metabolite) through plasma concentrations⩾100 ng ml^−1^.

The main limitations of our study are its retrospective nature and the relatively small number of patients included, which could potentially have biased survival analyses. However, our findings have potentially direct bedside implications, as evaluating sarcopenia on CT scan and BMI calculation are feasible in daily practice. This would enable closer follow-up of patients at risk and, therefore, avoid severe toxicities by early dose adjustments or therapeutic interventions when needed.

Conversely, patients devoid of sarcopenia and BMI \<25 kg m^−2^ could probably be treated with full-dose sunitinib without excessive risk, even when ECOG PS exceeds 1.

In conclusion, our results highlight the importance of assessing body composition, and suggest that the combination of sarcopenia and low BMI predicts early DLTs in mRCC patients treated with sunitinib.
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![**Distribution of BMI, muscle index and early DLT.** (**A**) Distribution of BMI, muscle index and early DLT for men. Symbols represent individual patients, filled triangles represent patients with early DLT. (**B**) Distribution of BMI, muscle index and early DLT for women. Symbols represent individual patients, filled triangles represent patients with early DLT.](bjc201358f2){#fig2}

![**Progression-free survival and overall survival.** (**A**) Progression-free survival in sarcopenic patients with low BMI compared with remaining patients. (**B**) Overall survival in sarcopenic patients with low BMI compared with remaining patients.](bjc201358f3){#fig3}

###### Baseline characteristics of patients treated with sunitinib

  **Characteristics**                                      **Males (*****n*****=38)**   **Females (*****n*****=23)**   **Total (*****n*****=61)**
  -------------------------------------------------------- ---------------------------- ------------------------------ ----------------------------
  Age (years), median (range)                              60 (29--83)                  59 (30--79)                    60 (29--83)
  **ECOG PS,** ***n*** **(%)**                                                                                         
  0                                                        14 (36.8)                    5 (21.7)                       19 (31.2)
  1                                                        19 (50)                      12 (52.2)                      31 (50.8)
  ⩾2                                                       5 (13.2)                     6 (26.1)                       11 (18)
  **Metastatic sites,** ***n*** **(%)**                                                                                
  1                                                        16 (42.1)                    11 (47.8)                      27 (44.3)
  2                                                        8 (21.1)                     6 (26.2)                       14 (23)
  3                                                        7 (18.4)                     5 (21.7)                       12 (19.7)
  ⩾4                                                       7 (18.4)                     1 (4.3)                        8 (13)
  **Specific metastatic sites,** ***n*** **(%)**                                                                       
  Lung                                                     22 (57.9)                    11 (47.8)                      33 (54.1)
  Liver                                                    2 (5.3)                      2 (8.7)                        4 (6.6)
  Bone                                                     20 (52.6)                    9 (39.1)                       29 (47.5)
  **MSKCC prognostic risk,** ***n*** **(%)**                                                                           
  Low risk                                                 5 (13.2)                     5 (21.7)                       10 (16.4)
  Intermediate risk                                        28 (73.6)                    13 (56.6)                      41 (67.2)
  High risk                                                5 (13.2)                     5 (21.7)                       10 (16.4)
  **Heng prognostic group,** ***n*** **(%)**                                                                           
  Favourable                                               5 (13.2)                     5 (21.7)                       10 (16.4)
  Intermediate                                             23 (60.5)                    13 (56.6)                      36 (59)
  Poor                                                     10 (26.3)                    5 (21.7)                       15 (24.6)
  Weight (kg), median (range)                              78 (50--124)                 62 (44--91)                    73 (44--124)
  BMI (kg m^−2^), median (range)                           25.9 (17.3--43.4)            24.2 (17.1--36.5)              24.9 (17.1--43.4)
  Underweight (BMI\<18.5), *n* (%)                         2 (5.3)                      3 (13)                         5 (8.2)
  Normal weight (18.5⩽BMI⩽24.9), *n* (%)                   14 (36.8)                    13 (56.5)                      27 (44.3)
  Overweight (25⩽BMI⩽29.9), *n* (%)                        12 (31.6)                    4 (17.5)                       16 (26.2)
  Obese (30⩽BMI), *n* (%)                                  10 (26.3)                    3 (13)                         13 (21.3)
  LBM (kg), median (range)                                 49.3 (32.2--65.9)            33.3 (24.9--40.3)              42.7 (24.9--65.9)
  Skeletal muscle L3 area (cm^2^), median (range)          158 (101--214)               105 (77--128)                  136 (77--214)
  Skeletal muscle L3 index (cm^2^ m^−2^), median (range)   51.6 (35.0--67.5)            40.9 (27.2--47.2)              46.2 (27.2--67.5)
  Sarcopenic, *n* (%)                                      24 (63.2)                    8 (34.8)                       32 (52.5)
  Sarcopenic and BMI \<25, *n* (%)                         13 (34.2)                    7 (30.4)                       20 (32.8)

Abbreviations: ECOG PS=Eastern Cooperative Oncology Group performance status; MSKCC=Memorial Sloan Kettering Cancer Center; BMI=body mass index (weight/height^2^); LBM=lean body mass; CT=computed tomography.

LBM calculated from the regression equation: whole LBM (kg)=0.30 × ((skeletal muscle at L3 using CT (cm^2^))+6.06).

###### Description of DLTs and therapy adjustments

  **Patient**   **Starting dose**                         **Grade 3 toxicities**          **Grade 2 toxicities**                       **Sarcopenia and BMI \<25**  **Therapy adjustment**       **Sunitinib after DLT (weeks)**
  ------------- ----------------------------------------- ------------------------------- ------------------------------------------- ----------------------------- ---------------------------- ---------------------------------
  1             37.5 mg CDD                               Proteinuria                     0                                                        No               37.5 mg CDD                  6
  2             25 mg CDD and 37.5 mg CDD after 2 weeks   0                               Nausea Proteinuria Hypertension Asthenia                 Yes              37.5 mg CDD                  8
  3             50 mg 4w/6                                Thrombocytopenia                Hypertension                                             Yes              37.5 mg CDD                  50
  4             50 mg 4w/6                                MAHA                            Asthenia                                                 Yes              PT, switch to temsirolimus   0
  5             50 mg 4w/6                                Hypothyroidism Asthenia         0                                                        Yes              PT, switch to everolimus     0
  6             50 mg 4w/6                                Hypertension                    Proteinuria                                              No               37.5 mg CDD                  37 (ongoing)
  7             37.5 mg CDD                               Hand-foot syndrome Stomatitis   Diarrhoea                                                No               25 mg CDD                    21
  8             37.5 mg CDD                               Asthenia                        0                                                        No               25 mg CDD                    150
  9             50 mg 4w/6                                Stomatitis                      Thrombocytopenia                                         No               37.5 mg CDD                  22
  10            50 mg 4w/6                                Proteinuria MAS                 Asthenia                                                 No               50 mg 4w/6                   33
  11            50 mg 4w/6                                Asthenia TMA                    0                                                        Yes              PT                           0
  12            50 mg 4w/6                                TMA RPLS                        Hypertension Asthenia                                    Yes              PT, switch to temsirolimus   0
  13            25 mg CDD                                 Hypertension                    Stomatitis Hypothyroidism Edema                          Yes              PT, switch to everolimus     0
  14            50 mg 4w/6                                Stomatitis Rash                 0                                                        Yes              37.5 mg CDD                  16 (ongoing)
  15            50 mg 4w/6                                Haemorrhagic rectocolitis       0                                                        No               PT, switch to sorafenib      0
  16            50 mg 4w/6                                Asthenia Anorexia               Proteinuria                                              No               25 mg CDD                    31
  17            50 mg 4w/6                                RLPS Asthenia                   0                                                        Yes              PT                           0
  18            50 mg 4w/6                                Nausea                          Hypertension Hand--foot syndrome Asthenia                Yes              37.5 mg CDD                  85

Abbreviations: DLT=dose-limiting toxicity; PT=permanent termination; CDD=continuous daily dosing; MAHA=microangiopathic haemolytic anaemia; TMA=thrombotic microangiopathy; MAS=macrophage activation syndrome; RPLS=reversible posterior leukoencephalopathy syndrome; 50 mg 4w/6=50 mg of sunitinib daily, 4 weeks on and 2 weeks off.

###### Anthropometric measurements in patients with or without early DLTs

  **Variable**                                 **Patients with early DLT, mean (s.d.)**   **Patients without early DLT, mean (s.d.)**   ***P*****-value**
  ------------------------------------------- ------------------------------------------ --------------------------------------------- -------------------
  Females                                                       *n*=9                                       *n*=14                               
  Age (years)                                                  62 (14)                                      56 (12)                           0.17
  Weight (kg)                                                  62 (12)                                      66 (13)                           0.39
  BMI (kg m^−2^)                                              24.4 (5.1)                                   24.5 (5)                           0.59
  BSA (m^2^)                                                 1.66 (0.15)                                  1.73 (0.19)                         0.18
  LBM (kg)                                                    30.6 (3.8)                                  35.3 (3.3)                        **0.01**
  Skeletal muscle L3 index (cm^2^ m^−2^)                      37.7 (6.5)                                   41.4 (4)                           0.17
  Sarcopenia, *n* (%)                                          5 (55.5)                                    3 (21.4)                           0.17
  Sarcopenia and BMI \<25 kg m^−2^, *n* (%)                    5 (55.5)                                    2 (14.2)                           0.06
  Males                                                         *n*=9                                       *n*=29                               
  Age (years)                                                 65.8 (6.2)                                    57 (12)                         **0.01**
  Weight (kg)                                                  72 (14)                                      86 (17)                         **0.03**
  BMI (kg m^−2^)                                              24.8 (5.3)                                  27.6 (5.4)                          0.18
  BSA (m^2^)                                                 1.84 (0.17)                                  2.04 (0.22)                       **0.02**
  LBM (kg)                                                    44.9 (8.4)                                  50.5 (7.1)                          0.13
  Skeletal muscle L3 index (cm^2^ m^−2^)                     49.3 (10.4)                                  52.3 (7.3)                          0.30
  Sarcopenia, *n* (%)                                          7 (77.8)                                    17 (58.6)                          0.43
  Sarcopenia and BMI \<25 kg m^−2^, *n* (%)                    5 (55.5)                                    8 (27.6)                           0.22
  Total                                                         *n*=18                                      *n*=43                               
  Age (years)                                                  64 (11)                                      56 (12)                         **0.006**
  Weight (kg)                                                67.2 (13.4)                                  79.4 (18.6)                       **0.007**
  BMI (kg m^−2^)                                               24.6 (5)                                   26.6 (5.4)                          0.10
  BSA (m^2^)                                                 1.75 (0.18)                                  1.94 (0.26)                       **0.004**
  LBM (kg)                                                    37.7 (9.7)                                  45.6 (9.4)                        **0.006**
  Skeletal muscle L3 index (cm^2^ m^−2^)                     43.5 (10.3)                                  48.7 (8.2)                        **0.02**
  Sarcopenia, *n* (%)                                         12 (66.7)                                    20 (46.5)                          0.17
  Sarcopenia and BMI\<25 kg m^−2^, *n* (%)                    10 (55.5)                                    10 (23.3)                        **0.01**

Abbreviations: DLT=dose-limiting toxicities; BMI=body mass index; BSA=body surface area; LBM=lean body mass. Bold entries indicate statistically significant values (*P*\<0.05).

###### Comparison between patients with or without sarcopenia and BMI\<25 kg m^−2^, and outcome during first cycle of treatment

                                                                              **Sarcopenic and BMI\<25 kg m**^**−2**^ (***n*****=20)**   **Non-sarcopenic or BMI\>25 kg m**^**−2**^ (***n*****=41)**    ***P*****-value**
  --------------------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------------- -------------------
  **Sunitinib starting dose,** ***n*** **(%)**                                                                                                                                                         
  25 or 37.5 mg, CDD                                                          2 (10)                                                     10 (24.4)                                                            0.30
  50 mg, 4 weeks/6                                                            18 (90)                                                    31 (75.6)                                                               
  **ECOG PS,** ***n*** **(%)**                                                                                                                                                                         
  0--1                                                                        14 (70)                                                    36 (87.8)                                                            0.15
  ⩾2                                                                          6 (30)                                                     5 (12.2)                                                                
  **MSKCC prognostic score,** ***n*** **(%)**                                                                                                                                                          
  Low risk                                                                    2 (10)                                                     8 (19.5)                                                             0.39
  Intermediate risk                                                           13 (65)                                                    28 (68.3)                                                               
  High risk                                                                   5 (25)                                                     5 (12.2)                                                                
  **Heng prognostic score,** ***n*** **(%)**                                                                                                                                                           
  Favourable                                                                  1 (5)                                                      9 (22)                                                               0.07
  Intermediate                                                                11 (55)                                                    25 (61)                                                                 
  Poor                                                                        8 (40)                                                     7 (17)                                                                  
  **Characteristics, median (range)**                                                                                                                                                                  
  Age (years)                                                                 61 (35--79)                                                58 (29--83)                                                          0.46
  Weight (kg)                                                                 64 (50--79)                                                78 (44--124)                                                       **0.001**
  Height (m)                                                                  1.73 (1.58--1.87)                                          1.70 (1.50--1.92)                                                    0.44
  BMI (kg m^−2^)                                                              23.0 (17.3--24.9)                                          27.1 (17.1--43.4)                                                 **\<0.001**
  BSA (m^2^)                                                                  1.75 (1.54--1.99)                                          1.96 (1.39--2.53)                                                  **0.009**
  Haemoglobin (g dl^−1^)                                                      12.1 (7.2--15.2)                                           12.7 (8.4--16.6)                                                     0.43
  Lymphocytes ( × 10^6^/l)                                                    1545 (310--2110)                                           1400 (560--4872)                                                     0.93
  Platelets ( × 10^9^/l)                                                      361 (222--725)                                             271 (124--517)                                                       0.06
  Albuminaemia (g l^−1^)                                                      40 (26--46)                                                39 (28--45)                                                          0.98
  CRP (g l^−1^)                                                               32.5 (1--147.1)                                            18 (1--298)                                                          0.87
  Creatininaemia (μℳ)                                                         84.5 (45--136.3)                                           98.5 (53--167.3)                                                   **0.02**
  Lumbar skeletal muscle index (cm^2^ m^−2^)                                  41.4 (27.2--54.5)                                          47.7 (37.7--67.5)                                                 **\<0.001**
  LBM (kg)                                                                    42.0 (24.9--53.1)                                          46.7 (32.3--65.9)                                                  **0.01**
  **DLT,** ***n*** **(%)**                                                                                                                                                                             
  Present                                                                     10 (50)                                                    8 (19.5)                                                           **0.01**
  Absent                                                                      10 (50)                                                    33 (80.5)                                                               
  **Permanent termination of sunitinib owing to toxicity,** ***n*** **(%)**                                                                                                                            
  Present                                                                     6 (30)                                                     1 (2.4)                                                            **0.003**
  Absent                                                                      14 (70)                                                    40 (97.6)                                                               
  **Prevalence of selected toxicities,** ***n*** **(%)**                                                                                                                                               
  Diarrhoea, grade 2--3                                                       0                                                          4 (9.8)                                                              0.29
  Grade 3 diarrhoea                                                           0                                                          0                                                                      1
  Hypertension, grade 2--3                                                    12 (60)                                                    14 (34.1)                                                            0.09
  Grade 3 hypertension                                                        6 (30)                                                     9 (22)                                                               0.53
  Asthenia, grade 2--3                                                        10 (50)                                                    16 (39)                                                              0.58
  Grade 3 asthenia                                                            3 (15)                                                     4 (9.8)                                                              0.67
  Hand--foot syndrome, grade 2--3                                             2 (10)                                                     2 (4.8)                                                              0.59
  Grade 3 hand--foot syndrome                                                 0                                                          1 (2.4)                                                                1
  Acute vascular toxicity (MAHA, TMA, RPLS), *n* (%)                          4 (20)                                                     0                                                                  **0.009**
  Number of grade 2 or 3 toxicities per patient, *n* (%)                                                                                                                                                    **0.008**
  0                                                                           1 (5)                                                      13 (31.7)                                                          **0.02**
  1                                                                           5 (25)                                                     11 (26.8)                                                              1
  2                                                                           8 (40)                                                     11 (26.8)                                                            0.37
  3                                                                           2 (10)                                                     6 (14.7)                                                               1
  4                                                                           4 (20)                                                     0                                                                  **0.009**
  0-1                                                                         6 (30)                                                     24 (58.5)                                                            0.055
  ⩾2                                                                          14 (70)                                                    17 (41.5)                                                               
  Number of grade 3 toxicities per patient, *n* (%)                                                                                                                                                         **0.04**
  0                                                                           6 (30)                                                     23 (56.1)                                                            0.06
  1                                                                           8 (40)                                                     15 (36.6)                                                              1
  ⩾2                                                                          6 (30)                                                     3 (7.3)                                                            **0.04**

Abbreviations: BMI=body mass index; BSA=body surface area; CDD=continuous daily dosing; DLT=dose-limiting toxicity; ECOG PS= Eastern Cooperative Oncology Group criteria performance status; MSKCC=Memorial Sloan Kettering Cancer Center; CRP=C-reactive protein; LBM=lean body mass; MAHA=microangiopathic haemolytic anaemia; TMA=thrombotic microangiopathy; RPLS=reversible posterior leukoencephalopathy syndrome. Bold entries indicate statistically significant values (*P*\<0.05).
